AI assistant
Gossamer Bio, Inc. — Director's Dealing 2021
Jun 23, 2021
32603_dirs_2021-06-22_1d355f6f-b82c-468c-ad0c-b8140df60480.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Gossamer Bio, Inc. (GOSS)
CIK: 0001728117
Period of Report: 2021-06-21
Reporting Person: Aranda Richard (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-21 | Common Stock | A | 15000 | — | Acquired | 219809 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-21 | Stock Option (Right to Buy) | $8.47 | A | 30000 | Acquired | 2031-06-21 | Common Stock (30000.0) | Direct |
Footnotes
F1: Represents a restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date.
F2: 25% of the total number of shares subject to the option will vest on June 21, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.